Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-1) infection has reached pandemic proportions. Forty years later, research has led to the approval of more than 30 antiretroviral drugs, while combination therapies have turned HIV-1 infection into a chronic, but manageable disease. Still, drug toxicity and acquired and transmitted drug resistance remain as major threats to therapy success. In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly those involving novel drug candidates such as lenacapavir or islatravir.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tips.2021.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the cost-utility of implementing HIV self-testing with digital-based supports.
Front Public Health
January 2025
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Introduction: HIV self-testing (HIVST) is an innovative strategy that has been shown to increase uptake of HIV testing compared to conventional facility-based testing. HIVST implementation with digital-based supports may help facilitate testing accessibility and linkage to care after a reactive self-test. Economic evidence around community-based implementation of HIVST is growing; however, economic evidence around digital-based HIVST approaches remains limited.
View Article and Find Full Text PDFTransitions through the HIV continuum of care in people enrolling in care with advanced HIV disease in Latin America.
IJID Reg
March 2025
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Objectives: Advanced HIV disease (AHD) at HIV care enrollment is common in Latin America and may bias cross-sectional care continuum estimates. We therefore explored the impact of AHD on HIV care continuum outcomes using a longitudinal approach.
Methods: We analyzed trajectories of 26,174 adult people with HIV enrolled at Caribbean, Central and South America network for HIV epidemiology (CCASAnet) sites (2003-2019) using multi-state Cox regression across five stages: (i) enrolled without antiretroviral therapy (no-ART); (ii) on ART without viral suppression (viral load ≥200 copies/m; ART + non-VS); (iii) on ART with viral suppression (viral load <200 copies/ml; ART + VS); (iv) lost to follow-up; (v) death.
Background: The proportion of people living with HIV (PLHIV) in Guangxi who are men who have sex with men (MSM) increased rapidly to nearly 10% in 2023; notably, over 95% of this particular population is currently receiving antiretroviral therapy (ART). This study aimed to describe the survival of MSM PLHIV, depict the characteristics and trends of changes in CD4 T cell counts, CD4/CD8 T cell ratio, and viral load, and explore immunological indicators that may be related to mortality during different stages of treatment.
Methods: Immunological indicators of MSM PLHIV receiving ART were extracted and categorized into baseline, mid-treatment, and last values.
Direct collaboration between hospitals and NGOs, an essential tool to reinforce linkage to care in people living with HIV.
Sci Rep
January 2025
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Gregorio Marañón General University Hospital, Calle Doctor Esquerdo, 46, 28007, Madrid, Spain.
With the aim of improving access and engagement to healthcare in people living with HIV (PLHIV), in 2022 Gregorio Marañón Hospital and the NGO COGAM developed a circuit for recruitment and referral to hospital. Program targeted PLHIV who were neither receiving antiretroviral treatment (ART) nor on medical follow-up (FU); but also, individuals at risk who underwent screening tests at the NGO and, if positive, were referred for confirmation. The result was an increase in annual new PLHIV seen in hospital by reaching a population who were, essentially, young men (94% male, median age 30 years), migrants (95%) with recent diagnosis of HIV (median 5 years) and who were recently arrived in Spain (median 5 months).
View Article and Find Full Text PDFMental health challenges and perceptions of stigma among youth living with HIV in Tanzania.
PLoS One
January 2025
Duke Global Health Institute, Durham, North Carolina, United States of America.
Youth living with HIV (YLWH) face psychosocial challenges and HIV-related stigma, which impact adherence to antiretroviral therapy (ART). This study was designed to understand better the change in mental health symptoms and experiences with stigma among YLWH in Tanzania who completed the original pilot Sauti ya Vijana (SYV), a mental health and life skills group intervention. YLWH who completed SYV and demonstrated a change of ≥2 points in either direction on their Patient Health Questionnaire PHQ-9 (depression screener) from baseline to 18 months were purposively sampled.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!